SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma

Andrew Davies

Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the update of the phase 3 SABRINA trial that was presented at the 20th Congress of the European Hematology Association (EHA). SABRINA evaluated subcutaneous versus intravenous rituximab in patients with previously untreated follicular lymphoma.

Share this video  
Follicular Lymphoma
Rituximab
EHA 2015
12th June 2015
More from Andrew Davies
Data on new therapeutic strategies in Hodgkin lymphoma
Subcutaneous rituximab versus intravenous rituximab – safety and efficacy results
Current research on diffuse large B-cell lymphoma (DLBCL)
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals